← Leaderboards
Yehenew M Agazie
West Virginia University
$3,908,639
Attributed
$3,908,639
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $498.7K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,908,639 · 6
By mechanism
R01$2,943,528 · 2
P20$965,111 · 4
Top collaborators
No co-investigators on record.
Most similar at West Virginia University
Same institution · by research overlap
- Laura F Gibson$10,658,122
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsCell TransformationSignal PathwayEpidermal Growth Factor ReceptorSignal TransductionTumorMalignant NeoplasmsBaseCell ProliferationMediator Of Activation ProteinNeoplasm MetastasisTumor GrowthTissuesProtein Tyrosine PhosphataseFutureBreastPhosphorylation SiteProtein OverexpressionMolecularMutantMediatingOverexpressionEpithelial To Mesenchymal Transition
Grant awards (14)
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer$336,263
R01 · FY2022 · CA · contact PI
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer$343,125
R01 · FY2021 · CA · contact PI
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer$343,125
R01 · FY2020 · CA · contact PI
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer$332,830
R01 · FY2019 · CA · contact PI
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer$343,125
R01 · FY2018 · CA · contact PI
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis$243,000
R01 · FY2011 · CA · contact PI
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis$250,515
R01 · FY2010 · CA · contact PI
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis$250,515
R01 · FY2009 · CA · contact PI
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis$250,515
R01 · FY2008 · CA · contact PI
SHP2-MEDIATED CROSS-TALK BETWEEN WNT AND EGFR/HER2 SIGNALING IN BREAST CANCER$243,230
P20 · FY2008 · RR · contact PI
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis$250,515
R01 · FY2007 · CA · contact PI
SHP2-MEDIATED CROSS-TALK BETWEEN WNT AND EGFR/HER2 SIGNALING IN BREAST CANCER$248,194
P20 · FY2007 · RR · contact PI
SHP2-MEDIATED CROSS-TALK BETWEEN WNT AND EGFR/HER2 SIGNALING IN BREAST CANCER$255,606
P20 · FY2006 · RR · contact PI
REGULATION OF CELL MORPHOLOGY AND TRANSFORMATION BY SHP2$218,081
P20 · FY2005 · RR